TRPM7 and myeloid sarcoma: Moreover, FTY720, an FDA‐approved MS drug, inhibits TRPM7 function, and VPC01091.4, an analog of FTY720, reduces cytokine release from inflammatory‐activated macrophage/microglia by inhibiting TRPM7 currents [78].